KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Raw Materials: 2023-2024

Historic Raw Materials for Aurinia Pharmaceuticals (AUPH) over the last 2 years, with Dec 2024 value amounting to $1.7 million.

  • Aurinia Pharmaceuticals' Raw Materials was N/A to $771,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $771,000, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 2.52% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Raw Materials stood at $1.7 million for FY2024, which was down 2.52% from $1.7 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Raw Materials peaked at $1.7 million during FY2023, and registered a low of $1.7 million during FY2024.
  • For the 2-year period, Aurinia Pharmaceuticals' Raw Materials averaged around $1.7 million, with its median value being $1.7 million (2023).
  • Data for Aurinia Pharmaceuticals' Raw Materials shows a maximum YoY declined of 2.52% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Aurinia Pharmaceuticals' Raw Materials stood at $1.7 million in 2023, then dropped by 2.52% to $1.7 million in 2024.